Clinical trials: Retinal Vascularisation
Neovascularization, Macular Degeneration
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
Background/aims: Aflibercept is an approved therapy for neovascular macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion and other retinal conditions.
- Conditions
- Neovascularization, Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion
- Trial name
- Zaltrap (NCT02486484)
- Testing
- ziv-aflibercept
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Rafic Hariri University Hospital
Branch Retinal Vein Occlusion
Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion
The purpose of this study is to determine whether intraocular injection of triamcinolone is effective in the treatment of macular edema in acute branch retinal vein occlusion.
- Trial name
- NCT00370266
- Testing
- Triamcinolone
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
AMD - Age-Related Macular Degeneration
Comparison of the Sensibility of Swept Source Optical Coherence Tomography Devices in the Detection of Neovascularisation in Large Pigment Epithelium Detachments
The goal of this observational study is to compare swept source optical coherence tomography devices ability to detect macular neovascularisation when there is a large pigment epithelium detachment higher than 250 microns
- Trial name
- NCT07143526
- Testing
- Optical Coherence Tomography Angiography (OCT-A)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University of Trieste
Choroidal Neovascularization, Macular Degeneration
Photodynamic and Pharmacologic Treatment of CNV
The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration…
- Trial name
- PBS (NCT00570193)
- Testing
- verteporfin (Visudyne), ranibizumab (Lucentis)
- Volunteers
- 41 people
- Sponsor
- Mid-Atlantic Retina Consultations, Inc.
Retinopathy of Prematurity
Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)
Eligible eyes are randomly assigned into two groups. Group A receive Fasudil eye drops (concentration 0.5 percent) twice daily. Group B, receive artificial tears drop with the same frequency.
- Trial name
- NCT04191954
- Testing
- Fasudil eye drops (concentration 0.5 percent), receive artificial tears drop
- Where
- Iran
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences